Who
Lisa DeFrancesco
SVP, IR and Corp Comm
Company insider
Files Form 4 as: SVP, IR and Corp Comm, Lexicon Pharmaceuticals; SVP, IR & Corp. Affairs, Intercept Pharmaceuticals.
In numbers
- Trades disclosed
- 22
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 1 Sep 2021
- Last trade
- 28 Feb 2026
- Last filed
- 3 Mar 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —24,674 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —128,190 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $110K74,572 at $1.47 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —24,674 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —128,190 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —24,674 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —128,190 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —24,674 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —128,190 | filing |
| 28 Feb 2026filed 3 Mar 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $110K74,572 at $1.47 | filing |
| 12 Feb 2026filed 17 Feb 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —257,530 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —386,300 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —257,530 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —386,300 at $0.00 | filing |
| 28 Feb 2025filed 3 Mar 2025 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —24,673 | filing |
| 28 Feb 2025filed 3 Mar 2025 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —24,673 | filing |
| 28 Feb 2025filed 3 Mar 2025 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $6,0949,096 at $0.67 | filing |
| 13 Feb 2025filed 18 Feb 2025 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —576,850 at $0.00 | filing |
| 13 Feb 2025filed 18 Feb 2025 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —384,570 at $0.00 | filing |
| 31 Dec 2021filed 4 Jan 2022 | Intercept Pharmaceuticals | SEC FORM 4 Code F | $8,829542 at $16.29 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.